Celgene (CELG): Cancer progress boosts biotech
2009-08-18 14:00:00 "Some sectors tend to do better than others in tough times; biotechnology often surprises investors in good times and bad," suggests Brandon Clay.In his Invest with an Edge advisory service, the growth stock advisor looks to Celgene Corporation (NASDAQ: CELG), a player in developing cancer treatments. Here's his review."This sometimes-perilous market niche can make or break a portfolio depending on several factors: drug pipeline, continued investment, market factors, and government approvals."Biotech stock performance is often hostage to government action – or inaction. If the FDA approves a particular compound, the company’s shares can jump wildly higher. Denial can make a stock crater. "However, despite the risks, there are times when we believe that individual biotech stocks make sense -- such as our latest recommendation for Celgene."The company recently reported earnings; blood cancer products pushed second quarter ...
Celgene (CELG): Biopharma bet
2009-07-21 14:00:00 Celgene (NASDAQ: CELG), which develops treatments for cancer and immune-inflammatory diseas-e, is a stock of the month," from Dennis Slothower in Stealth Stocks."The drug and cell therapies developed by CELG are designed to treat life-threatening diseases or chronic debilitating conditions where patients are poorly served by current therapies. "CELG is investing in a range of innovative therapeutic programs that are investigating ways to treat and manage chronic diseases by targeting the disease source through multiple mechanisms of action. "Its three hematology products significantly impact survival of patients with cancer and other diseases. "The company continues to develop breakthrough products in areas of unmet medical need, creating one of the deepest and most diverse clinical pipelines in hematology and severe inflammatory diseases. "Despite a very challenging environment, CELG’s global reven...
Celgene (CGNE): Offense and defense
2009-06-22 06:00:00 "Biotech company Celgene Corp. (NASDAQ: CELG) is a prime example of a stock that plays both offense and defense," says Ian Wyatt.In his Top Stock Insights, he explains, "The valuation is low and growth is attractive. With the pipeline of products in development, Celegene offers investors a huge upside potential." Here's his review."Celgene offers investors a steady product base, a variety of drug treatments in development and a cash pile ready to purchase existing technologies."Celgene engages in the discovery of therapies designed to treat cancer and immune-inflammatory related diseases. They have a number of products at the commercial stage. "Their commercial stage products are REVLIMID®, THALOMID® and VIDAZA®. Celgene is also researching stem cells derived from the human placenta as well as from the umbilical cord, thus tapping into a promising new technology while avoiding the political and ethical questions dogging o...
Biotech expert bets on Celgene (CELG)
2009-05-13 06:00:00 "Celgene (NASDAQ: CELG) recently reported a first-quarter profit on higher sales of the multiple myeloma drug Revlimid," notes John McCamant in The Medical Technology Stock Letter."The company earned $162.9 million, or $0.35 per share, compared with a loss of $1.64 billion, or $3.98 per share, in the year-earlier period."The 2008 period included costs for the $1.74 billion purchase of Pharmion. Without that and other charges, it would have earned $0.36 per share. Revenue rose 31 percent to $605.1 million from $462.6 million. "Excluding charges in the most recent first quarter, the company said it earned $0.44 per share beating the Wall Street consensus by a penny, expected profit $0.43 per share on revenue of $602.1 million. "The first-quarter boost was primarily driven by market share gains for Revlimid. Sales of the blood cancer drug rose 26% to $362.5 million. "The company expects profit between $2.05 and $2.15 ...
Celgene (CELG): Selloff opportunity
2009-04-06 14:00:00 "After warning that it would only achieve the low end of its previous guidance range for 2009, Celgene (NASDAQ: CELG) sold off significantly," notes biotech expert John McCamant. Nevertheless, in his The Medical Technology Stock Letter he sees the selloff as any opportunity, calling the company a "great growth story.""Celgene pre-announced 1Q 09 revenues of $600 million, which was significantly below Wall Street consensus estimates of $640-$650 million."The earnings miss was completely unexpected, and has partially shaken the belief that the Big Bios would be able to deliver solid earnings despite the economic problems."Nevertheless, we remain positive on the CELG story because we continue to believe that Revlimid is emerging as a major franchise in cancer. The company has executed very well in the lab by creating Revlimid as a better drug that its parent Thalomid. "The improved efficacy and safety profile of Revlimid posit...
Celgene (CELG): Strong growth in biotech
2009-02-20 06:00:00 "Celgene (http://www.thestockadvisors.co-m/quote.htm?sym=celg) (NASDAQ: CELG (http://www.thestockadvisors.co-m/quote.htm?sym=celg)) reported their fourth quarter and year end numbers which showed strong revenue growth." observes biotech sector expert John McCamant (http://www.thestockadvisors.co-m/ccount/click.php?id=2856 ).The editor of The Medical Technology Stock Letter (http://www.thestockadvisors.co-m/ccount/click.php?id=2856 ) explains, "We remain excited about CELG’s growth prospects and management’s ability to deliver the goods." Here's his review."Total revenue for the quarter grew 50% to $623 million, with the primary driver being Revlimid sales of $369.4 million. Sales of their two other drugs, Thalomid and Vidaza generated $126.8 million and 69.7 million, respectively."The company also reiterated their 2009 financial outlook; CELG expects to report earnings in the range of $2.05 per share to $2.15 per share, which is well below analyst’s current estimat...
Celgene: Blockbuster biotech bet
2008-11-10 06:00:00 "The medical arena has long been my favorite sectors; perhaps the best opportunities within the medical sector will be with companies who provide life-saving products for the treatment of serious diseases," says Dave Dyer (http://www.thestockadvisors.co-m/ccount/click.php?id=2551).In- The Dave Dyer Newsletter (http://www.thestockadvisors.co-m/ccount/click.php?id=2551), he explains "That is why Celgene (http://www.thestockadvisors.co-m/quote.htm?sym=celg) (NASDAQ: CELG (http://www.thestockadvisors.co-m/quote.htm?sym=celg)) is an excellent choice in this economy." Here's his look at this recession-resistant company."Celgene is a multinational biopharmaceutical company with a $29 billion market cap and no debt."Revlimid is their blockbuster drug with multi-billion dollar potential. It was first approved by the FDA in 2005, and it has many good years of patent protection ahead of it."Revlimid delays the onset of progression of deadly diseases -- leprosy and multiple myeloma. No wonder it...
Celgene (CELG): Breakout biotech buy
2008-07-07 05:00:00 Biotechnology player Celgene (http://www.thestockadvisors.co-m/quote.htm?sym=celg) (NASDAQ: CELG (http://www.thestockadvisors.co-m/quote.htm?sym=celg)) is a new buy from Leo Fasciocco (http://www.thestockadvisors.co-m/ccount/click.php?id=2163), whose Ticker Tape Digest (http://www.thestockadvisors.co-m/ccount/click.php?id=2163) focuses on stocks that are breaking out from technical bases. "CELG has broken out from a 3-month flat base and has moved into position to make an all-time high. It just needs to hurdle 75.44. The stock has been one of the best performers in the medical sector having soared from 60 to 69 in the past six years. It is a market leader long-term."CELG markets Thalomid to treat multiple myeloma and Revlimid, a less toxic thalidomide derivative, to treat MDS and multiple myeloma. The acquisition of Pharmion gave CELG global rights to Thalomid as well as MDS drug Vidaza. CELG also has discovery capabilities in cell-signaling pathways and stem cell research."CELG has ap...
Biotech experts bet on Celgene (CGNE)
2008-04-25 07:00:00 Two top advisors -- each with a noted expertise in the biotech sector -- have both been long-term fans of Celgene (http://www.thestockadvisors.co-m/quote.htm?sym=celg) (NASDAQ: CELG (http://www.thestockadvisors.co-m/quote.htm?sym=celg)), with both holding the stock in their respective model portfolios. Here, Nate Pile (http://www.thestockadvisors.co-m/ccount/click.php?id=1958), editor of Nate's Notes (http://www.thestockadvisors.co-m/ccount/click.php?id=1958), and John McCamant (http://www.thestockadvisors.co-m/ccount/click.php?id=1959), editor of The Medical Technology Stock Letter (http://www.thestockadvisors.co-m/ccount/click.php?id=1959), each take a look at the long-term prospects for this leading biotech firm.Nate Pile explains, "Now that the Pharmion merger is behind us, it appears that investors are once again recognizing Celgene for what it is – namely, one of the premier stories in the biopharmaceutical space. "As I have said a number of times before, if I could only o...
Biotech expert favors Celgene (CGNE)
2008-01-25 07:00:00 "One of our favorite stock ideas for 2008 is Celgene (quote.htm?sym=celg)(NASDAQ: CELG (quote.htm?sym=celg))," says biotech expert John McCamant (ccount/click.php?id=1620), editor of The Medical Technology Stock Letter (ccount/click.php?id=1620). Here is his review."The company is focused on the development of new and improved treatments for various cancers and other severe, immune, inflammatory conditions, and is well on their way to becoming a major global biopharmaceutical entity. "Over the years, we have watched management consistently deliver on their promises to their shareholders and create additional value. The most notable cancer drugs at CELG are Thalidomide and Revlimid (a second-generation version of Thalidomide)."These are oral therapies that have become the cornerstone in the treatment of multiple myeloma (MM), and which are in clinical development for many other blood-borne cancers, including non-Hodgkin’s lymphoma (NHL) and CLL. "These products are on track...
Celgene (CELG)
2007-08-17 01:48:00 No counting, no zigzags, no motive waves either at this time, just simple beauty, could be called holder paradise or tunneling paradise, that yellow line is simple moving average-200.
By: Just Charts
Cramer Celgene (CELG) Mad Money Picks
2007-08-08 19:43:00 Celgene (CELG) is one of the stocks with the most bullish mentions on Mad Money with Jim Cramer. It has been featured 13 times as a stock to buy in the special section. Cramer has called it a favorite of his and has predicted that it could be a possible takeover target ...see Chart...
Cramer Celgene (CELG) Mad Money Picks
2007-08-06 17:50:00 Celgene (CELG) is one of the stocks with the most bullish mentions on Mad Money with Jim Cramer. It has been featured 13 times as a stock to buy in the special section. Cramer has called it a favorite of his and has predicted that it could be a possible takeover target a total of 3 times as lately as 4/30/2007. Bob Hugin, President and CEO of Celgene has been a guest on Mad Money's "On The Line" segment 3 seperate times, including once on Mad Money's Back to School Tour at University of Virginia's Darden Business School.
By: stockTagger
|
|
 |
|
 |
